Moderna Files 2025 Proxy Statement: Executive Compensation Details
Ticker: MRNA · Form: DEF 14A · Filed: Mar 11, 2025 · CIK: 1682852
| Field | Detail |
|---|---|
| Company | Moderna, Inc. (MRNA) |
| Form Type | DEF 14A |
| Filed Date | Mar 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: MRNA
TL;DR
Moderna's proxy statement is out, detailing exec pay and board stuff for 2024. Check it for shareholder votes.
AI Summary
Moderna, Inc. filed its Definitive Proxy Statement (DEF 14A) on March 11, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, board of directors, and other corporate governance matters. Key information includes compensation details for Named Executive Officers (NEOs) and Non-PEO NEOs, as well as equity awards granted and their year-end fair values.
Why It Matters
This filing provides shareholders with crucial information about how executive compensation is structured and approved, impacting company performance and shareholder value.
Risk Assessment
Risk Level: medium — Proxy statements can reveal information about executive compensation, potential conflicts of interest, or shareholder proposals that could impact the company's stock price.
Key Numbers
- 20250311 — Filing Date (Date the DEF 14A was filed with the SEC)
- 20250430 — Report Period End Date (Conformed period of report for the filing)
- 2024-12-31 — Fiscal Year End (Moderna's fiscal year end)
Key Players & Entities
- Moderna, Inc. (company) — Filer of the DEF 14A
- 325 BINNEY STREET (address) — Moderna's business and mailing address
- CAMBRIDGE (location) — City of Moderna's headquarters
- MA (location) — State of Moderna's headquarters
- 02142 (zip_code) — Zip code of Moderna's headquarters
- Moderna Therapeutics, Inc. (company) — Former company name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding the company's annual meeting of stockholders, including details on director nominations, executive compensation, and other corporate governance matters.
When was this Definitive Proxy Statement filed with the SEC?
This filing was made on March 11, 2025.
What is Moderna, Inc.'s fiscal year end?
Moderna, Inc.'s fiscal year ends on December 31st.
What was Moderna's former company name?
Moderna's former company name was Moderna Therapeutics, Inc.
What is the SEC file number for Moderna, Inc. related to the 1934 Act?
The SEC file number is 001-38753.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 11, 2025 regarding Moderna, Inc. (MRNA).